- Trial Phase
- Approved/Marketed (Phase 3 for carcinoid syndrome ongoing)
- Time to Market
- Already approved and launched (FDA approval Sept 2025, EU approval April 2026)
- Why 4/10
- PALSONIFY is already FDA-approved (Sept 2025) and EU-approved (April 2026), so the defining binary catalysts have passed. The next hard catalyst is the Phase 3 CAREFNDR topline readout for carcinoid syndrome, but with first patient randomized Nov 2025 and 141 patients to enroll, this is >12 months away. As an approved drug with no near-term binary, impactScore is 4.
Watch quarterly PALSONIFY sales growth and prescription trends as the commercial launch ramps — Q1 2026 revenue of $10.3M already beat expectations. The Phase 3 CAREFNDR readout for carcinoid syndrome is the next major binary catalyst (likely 2027). The stock trades at ~$37 with a mean analyst target of ~$83, implying ~123% upside, though the company remains unprofitable (FY2026 EPS consensus -$4.78).
Price Chart
Executive Summary
PALSONIFY (paltusotine) is Crinetics Pharmaceuticals' first approved and launched product — a once-daily oral treatment for acromegaly, a rare endocrine disorder. The FDA approved it on Sept 25, 2025 (stock surged 30.5% that day), and the EU followed on April 27, 2026. Early commercial traction is strong: Q4 2025 net revenue of $5.4M, Q1 2026 revenue of $10.3M, with >200 patient starts and 125+ unique prescribers. The key competitive edge is that it's the only oral once-daily therapy in a market historically dominated by injectables (Novartis' Sandostatin, Ipsen's Somatuline). S&P Global projects blockbuster peak sales of ~$1B by 2034. The pipeline expansion into carcinoid syndrome (Phase 3 CAREFNDR) adds upside optionality. The stock at ~$37 trades well below the mean analyst target of ~$83, with strong institutional support (FMR, Vanguard, BlackRock) and a strong-buy consensus (20 buys, 2 holds, 0 sells). Risks include commercial execution in a rare-disease market, competition from established injectable therapies, pipeline setbacks, and the company's pre-profitability status.
How It Works
PALSONIFY is a once-daily pill that mimics the body's natural somatostatin hormone. It binds to somatostatin receptors to block the release of excess growth hormone, which is the root cause of acromegaly (a rare condition where the pituitary gland produces too much growth hormone, causing bone overgrowth, joint pain, and organ damage). It's the first oral treatment for acromegaly, replacing current injectable therapies.
Trial Status
PALSONIFY gained FDA approval on Sept 25, 2025, and European Commission approval on April 27, 2026, based on pivotal Phase 3 PATHFNDR-1 and PATHFNDR-2 trials in acromegaly. A Phase 3 CAREFNDR trial (141 patients, randomized, placebo-controlled) for carcinoid syndrome began enrolling in November 2025. A Phase 2 study in carcinoid syndrome has completed with positive results.
The Two-Sided Case
Upcoming Catalysts
- Quarterly commercial sales updates — next earnings report expected early August 2026 for Q2 2026 PALSONIFY revenue
- Phase 3 CAREFNDR trial enrollment completion and eventual topline readout for carcinoid syndrome (likely 2027)
- Japan regulatory decision on orphan drug status and potential approval for acromegaly
- Payer formulary decisions and EU launch reimbursement progress
- Any data presentations at ENDO 2027 medical conference
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Crinetics Pharmaceuticals, Inc. PRESS-RELEASE CRNX ·Originating report